About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- COVID-19 ranges from mild URI symptoms to pneumonia, ARDS, thrombosis, and post-acute sequelae
- Outpatient high-risk mild/moderate COVID-19: nirmatrelvir-ritonavir within 5 days is preferred when no contraindicating drug interactions or renal/hepatic issues exist
- Three-day IV remdesivir within 7 days is the preferred alternative when nirmatrelvir-ritonavir cannot be used
- Systemic corticosteroids are used in hospitalized patients who require oxygen; avoid steroids in mild outpatient disease without another indication
- Hospitalized severe disease management depends on oxygen requirement and may include dexamethasone, remdesivir, anticoagulation, and immunomodulators in selected patients
Overview
COVID-19 is caused by SARS-CoV-2. Current management focuses on early antiviral therapy for high-risk outpatients, supportive care for mild disease, oxygen and anti-inflammatory therapy for hypoxemic hospitalized patients, and prevention through vaccination.
Epidemiology
COVID-19 remains endemic in the United States with periodic waves. Severe disease risk is highest in older adults, immunocompromised patients, pregnant patients, people with chronic disease, obesity, and those not up to date with vaccination.
Clinical Features
Symptoms
Progressive or acute dyspnea depending on severity and underlying cause
Cough, chest discomfort, fatigue, or exercise limitation
Fever, weight loss, night sweats, or hemoptysis when infection or malignancy is present
Syncope, confusion, severe hypoxemia, or rapidly worsening respiratory distress
Symptoms may be absent when the condition is detected incidentally
Signs
Abnormal breath sounds, crackles, wheeze, dullness, or reduced air entry depending on pathology
Tachypnea, tachycardia, or oxygen desaturation when clinically significant
Cyanosis, hypotension, altered mental status, or respiratory exhaustion
Clubbing, lymphadenopathy, cachexia, or signs of chronic disease when present
Physical examination can be normal in early or mild disease
Investigations
First-line
Focused history and examinationIdentify timing, exposures, smoking, travel, medications, immune status, occupational risks, and red flags
Pulse oximetryRapid assessment of oxygenation and severity
Chest imagingChest X-ray is often initial; CT is used when more anatomic detail, malignancy risk, complications, or alternative diagnosis must be clarified
Second-line
Laboratory testingCBC, CMP, inflammatory markers, cultures, viral testing, autoimmune tests, or disease-specific markers depending on presentation
Pulmonary function testingUseful for chronic dyspnea, obstructive/restrictive patterns, DLCO, and treatment response
Microbiology or pathologySputum studies, cytology, biopsy, or fluid analysis when infection, cancer, or inflammatory disease is suspected
Specialist
Specialist referralPulmonology, infectious disease, oncology, sleep medicine, critical care, or thoracic surgery depending on diagnosis and severity
Advanced testingBronchoscopy, PET-CT, sleep study, HRCT, echocardiography, or interventional radiology procedures when indicated
1
Initial management
- Assess severity, oxygenation, hemodynamics, airway risk, and need for hospital or ICU care
- Treat immediately reversible threats such as hypoxemia, bronchospasm, sepsis, PE, pneumothorax, or respiratory failure
- Use diagnosis-specific guideline therapy rather than empiric escalation without a working differential
2
Definitive treatment
- Treat the underlying cause according to US guideline recommendations
- Use imaging, microbiology, pathology, physiology, and risk stratification to guide therapy
- Escalate to procedural or specialist management when medical therapy is insufficient or diagnosis remains uncertain
3
Follow-up and prevention
- Arrange follow-up imaging or functional testing when recommended
- Address smoking cessation, vaccination, occupational exposure, medication toxicity, and comorbidity optimization
- Educate patients on red flags including worsening dyspnea, hemoptysis, syncope, hypoxemia, or persistent fever
Complications
- Respiratory failure: Severe disease can progress to hypoxemia, hypercapnia, or need for ventilatory support
- Secondary infection: Damaged or obstructed lung is prone to bacterial infection
- Pulmonary hypertension: Chronic hypoxemia or parenchymal disease can increase pulmonary vascular resistance
- Delayed diagnosis: Incidental or nonspecific presentations may hide malignancy, TB, PE, or ILD
- Treatment toxicity: Antimicrobials, corticosteroids, anticoagulants, chemotherapy, or procedures can cause harm
USMLE Step 2 CK Exam Tips
- 1High-risk outpatient within 5 days of symptoms = nirmatrelvir-ritonavir if no major contraindication
- 2If nirmatrelvir-ritonavir cannot be used, 3-day outpatient remdesivir within 7 days is the preferred alternative
- 3Dexamethasone is for COVID-19 patients who need oxygen; do not give steroids for mild disease without hypoxemia
- 4Elevated D-dimer alone does not diagnose PE; use clinical probability and imaging when PE is suspected
- 5Silent hypoxemia can occur; pulse oximetry matters even if dyspnea seems modest
- 6Drug interactions are the classic nirmatrelvir-ritonavir trap because ritonavir strongly inhibits CYP3A
practicetest your knowledge on covid-19 (current management)Apply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — respiratory and beyond.
open q-bank